News | July 10, 2023
Novavax's Nuvaxovid receives full marketing authorization in the EU
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
Supply readiness follows months of manufacturing to ensure timely and ample supply
This request for withdrawal of the two dossiers was made after necessary consultations and receiving guidance from EMA
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
The company increases its efficiency and is able to face the growing demand for its services.
The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Subscribe To Our Newsletter & Stay Updated
